In 2026, the biopharmaceutical world is undergoing a silent revolution in how cell lines are managed, with the global High-Density (HD) cell banking market reaching a pivotal valuation of nearly $15.5 billion. For years, "seed train" expansion—the process of growing a few cells into a massive production batch—was a bottleneck that took weeks of manual labor and multiple intermediate...